Description de l'entreprise
Prothena Corporation plc is a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Gene G. Kinney |
| Conseil d'administration |
| Tran B. Nguyen, Brandon Smith, Carol D. Karp, Dr. Hideki Garren, Dr. Wagner M. Zago, Karin L. Walker, Michael J. Malecek, Radhika Tripuraneni |
| Conseil de surveillance |
| Dr. Lars G. Ekman, Dennis J. Selkoe, Dr. Anders O. Härfstrand, Dr. Christopher S. Henney, Dr. Gene G. Kinney, Oleg Nodelman, Paula K. Cobb, Richard T. Collier, Sanjiv Patel, Shane M. Cooke |
Données de l'entreprise
| Nom: |
Prothena Corporation Plc. |
| Adresse: |
77 Sir John Rogerson’s Quay, Block C,Grand Canal Docklands, Dublin 2, D02 VK60, Ireland |
| Téléphone: |
+353-1-236-2500 |
| Fax: |
+353-1-902-3510 |
| Courriel: |
info@prothena.com
|
| Internet: |
https://www.prothena.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
- |
